Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting a proposed sale of 36,750 shares of Common Stock via the exercise of stock options on 04/17/2026.
The filing also records that 200,000 shares were sold under a 10b5-1 plan on 04/06/2026 by Kerry Wentworth for $903,550.
Nuvation Bio Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. The meeting will be held via live audio webcast at www.virtualshareholdermeeting.com/NUVB2026, with a record date of March 25, 2026.
Stockholders will vote on electing three directors to serve until the 2029 annual meeting, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. Holders of 346,685,831 Class A shares and 1,000,000 Class B shares are entitled to one vote per share.
The board is classified into three classes with seven total members and has determined that six directors, including the lead independent director, are independent under NYSE standards. Non-employee directors generally receive cash retainers plus annual stock option grants, while executive pay combines salary, annual performance-based bonuses and equity awards.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options for a total of 200,000 shares of Class A Common Stock on April 6, 2026, at exercise prices of $1.87 and $1.94 per share. The same day, Wentworth sold 200,000 shares in open-market transactions at a weighted-average price of $4.5178 per share, with individual sale prices ranging from $4.44 to $4.64, pursuant to a pre-arranged Rule 10b5-1 trading plan. After these transactions, Wentworth directly holds 53,000 shares of Class A Common Stock.
Nuvation Bio Inc. reported that its Chief Medical Officer, Dongfang Liu, received a grant of stock options covering 748,130 shares of common stock. The award is classified as a grant or other acquisition rather than an open-market purchase.
According to the terms, the option vests as to 25% of the underlying shares on the one-year anniversary of February 27, 2026, with the remaining portion vesting in equal monthly installments over the following 36 months. Vesting is conditioned on Dr. Liu’s continuous service with the company on each applicable vesting date.
Nuvation Bio Inc. reported that officer Makunje Moses received new equity awards. On February 27, 2026, Moses was granted stock options for 224,439 shares at an exercise price of $0.00 per share and 50,761 shares of Class A Common Stock as restricted stock units (RSUs).
The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months, contingent on continued service. The RSUs vest in four equal annual installments on the issuer’s quarterly vesting date following each of the first four anniversaries from February 27, 2026, also conditioned on continued service.